Company: NIVFW
Filing Date: 2025-09-18
Form Type: F-1
Source: 0001213900-25-088927
Chunk: 149

Company: NewGenIvf Group Ltd
Filing Date: 2025-09-18
Form: F-1
Chunk 149
---
 reputation in its industry, which in turn attracted potential business partners to approach NewGenIvf
to negotiate cooperations and referrals. Over the years, NewGenIvf sends representatives to medical expos mostly held in the PRC to approach
potential business partners and establish new partnerships by entering into agency agreements with each agent. NewGenIvf has become a
significant partner with approximately 90 fertility service agents in China as well as in India. Normally, each agency agreement has a
maximum term of one year, which is renewable upon mutual agreement. Agents typically market and promote NewGenIvf’s services by
word-to-mouth referrals and other measures and NewGenIvf pays the agents commission at a range of 10% to 25% of the treatment fees upon
the completion of client’s treatment. Normally, agents provide potential clients’ contact information to the sales team of
NewGenIvf, who then approach potential clients and provide consultation on services. With its partnerships in various countries, NewGenIvf
believes it is able to better benefit from the growing market opportunities.

<div align='center'>87</div>

Exclusively Owned and Licensed Technology for Family Planning and Access to Mature Fertility Technologies

NewGenIvf believes that its
licenses and/or access to mature technologies contribute to its ability to identify and tailor ARS services to individual patient’s
needs. These technologies include:

| ● | Preimplantation Genetic Screening (“PGS”): PGS is used in parallel with an IVF treatment cycle. PGS is the practice of determining the presence of aneuploidy (either too many or too few chromosomes) in a developing embryo. PGS improves success rates of in vitro fertilization by ensuring the transfer of euploid embryos that have a higher chance of implantation and resulting in a live birth. PGS has improved clinical outcomes for NewGenIvf by achieving a higher implantation rate of 70.9% and reducing miscarriage rates by 26.6%. |

| ● | Next-Generation Sequencing (“NGS”): NGS is a high-throughput technology for determining the sequence of deoxyribonucleic acid (“DNA”) or ribonucleic acid (“RNA”) to study genetic variation associated with diseases or other biological phenomena. NGS determines the sequence of a sample all at once by using parallel sequencing. Traditional Sanger sequencing determines the sequence of a sample one section at a time. Sequencing thousands of gene fragments simultaneously with NGS reduces time and cost